Why do Karyopharm’s delay and Amgen’s Imdelltra push signal selective biotech markets?

The article says both developments reflect a highly selective biotech environment. Karyopharm’s extra month shows a company preserving options while negotiating with creditors or seeking a deal, while Amgen’s move to broaden Imdelltra use shows established pharma still investing in oncology assets with clearer commercial potential.